AU594087B2 - Recombinant vaccinia virus sxpresses hybrid polypeptides on virus infected cell surface - Google Patents

Recombinant vaccinia virus sxpresses hybrid polypeptides on virus infected cell surface Download PDF

Info

Publication number: AU594087B2
Authority: AU; Australia
Prior art keywords: virus; polypeptide; recombinant; antigen; vaccinia virus
Prior art date: 1985-08-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU63701/86A

Other languages

English (en)

Other versions

AU6370186A (en

Inventor

Stirling John Edwards

Christopher John Langford

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Saramane Pty Ltd

Original Assignee

Walter and Eliza Hall Institute of Medical Research

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-08-29

Filing date

1986-08-29

Publication date

1990-03-01

1986-08-29 Application filed by Walter and Eliza Hall Institute of Medical Research filed Critical Walter and Eliza Hall Institute of Medical Research

1987-03-24 Publication of AU6370186A publication Critical patent/AU6370186A/en

1990-03-01 Application granted granted Critical

1990-03-01 Publication of AU594087B2 publication Critical patent/AU594087B2/en

1992-01-23 Assigned to SARAMANE PTY LTD reassignment SARAMANE PTY LTD Alteration of Name(s) in Register under S187 Assignors: WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH, THE

2006-08-29 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims description 80
102000004196 processed proteins & peptides Human genes 0.000 title claims description 74
229920001184 polypeptide Polymers 0.000 title claims description 73
241000700605 Viruses Species 0.000 title claims description 64
241000700618 Vaccinia virus Species 0.000 title claims description 52
210000004027 cell Anatomy 0.000 title description 71
239000000427 antigen Substances 0.000 claims description 26
230000002163 immunogen Effects 0.000 claims description 26
108091007433 antigens Proteins 0.000 claims description 23
108020004414 DNA Proteins 0.000 claims description 22
102000036639 antigens Human genes 0.000 claims description 22
241000223960 Plasmodium falciparum Species 0.000 claims description 20
206010035500 Plasmodium falciparum infection Diseases 0.000 claims description 17
108091026890 Coding region Proteins 0.000 claims description 14
102000053602 DNA Human genes 0.000 claims description 8
101710132601 Capsid protein Proteins 0.000 claims description 5
101710094648 Coat protein Proteins 0.000 claims description 5
101710125418 Major capsid protein Proteins 0.000 claims description 5
101710141454 Nucleoprotein Proteins 0.000 claims description 5
101710083689 Probable capsid protein Proteins 0.000 claims description 5
102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims description 4
108060003951 Immunoglobulin Proteins 0.000 claims description 4
102000018358 immunoglobulin Human genes 0.000 claims description 4
210000004369 blood Anatomy 0.000 claims description 2
239000008280 blood Substances 0.000 claims description 2
238000011160 research Methods 0.000 claims description 2
101710137302 Surface antigen S Proteins 0.000 description 69
108090000623 proteins and genes Proteins 0.000 description 47
206010046865 Vaccinia virus infection Diseases 0.000 description 26
208000007089 vaccinia Diseases 0.000 description 26
150000001413 amino acids Chemical class 0.000 description 25
102000004169 proteins and genes Human genes 0.000 description 24
241000283973 Oryctolagus cuniculus Species 0.000 description 23
235000018102 proteins Nutrition 0.000 description 23
239000013612 plasmid Substances 0.000 description 22
235000001014 amino acid Nutrition 0.000 description 21
239000012634 fragment Substances 0.000 description 20
230000003053 immunization Effects 0.000 description 16
238000002649 immunization Methods 0.000 description 12
208000015181 infectious disease Diseases 0.000 description 11
239000013598 vector Substances 0.000 description 11
229920004929 Triton X-114 Polymers 0.000 description 10
238000010367 cloning Methods 0.000 description 10
238000000034 method Methods 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
241000699670 Mus sp. Species 0.000 description 9
108091034117 Oligonucleotide Proteins 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
239000012528 membrane Substances 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
230000004044 response Effects 0.000 description 7
KQPKMEYBZUPZGK-UHFFFAOYSA-N 4-[(4-azido-2-nitroanilino)methyl]-5-(hydroxymethyl)-2-methylpyridin-3-ol Chemical group CC1=NC=C(CO)C(CNC=2C(=CC(=CC=2)N=[N+]=[N-])[N+]([O-])=O)=C1O KQPKMEYBZUPZGK-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
101001111984 Homo sapiens N-acylneuraminate-9-phosphatase Proteins 0.000 description 6
102000018697 Membrane Proteins Human genes 0.000 description 6
108010052285 Membrane Proteins Proteins 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 6
102100023906 N-acylneuraminate-9-phosphatase Human genes 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
238000005119 centrifugation Methods 0.000 description 6
238000010790 dilution Methods 0.000 description 6
239000012895 dilution Substances 0.000 description 6
108091033380 Coding strand Proteins 0.000 description 5
238000012286 ELISA Assay Methods 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
238000010276 construction Methods 0.000 description 5
238000003119 immunoblot Methods 0.000 description 5
230000005847 immunogenicity Effects 0.000 description 5
230000003834 intracellular effect Effects 0.000 description 5
244000045947 parasite Species 0.000 description 5
238000010186 staining Methods 0.000 description 5
108010076504 Protein Sorting Signals Proteins 0.000 description 4
229960000583 acetic acid Drugs 0.000 description 4
238000013459 approach Methods 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
230000002209 hydrophobic effect Effects 0.000 description 4
238000002372 labelling Methods 0.000 description 4
210000004962 mammalian cell Anatomy 0.000 description 4
229960005486 vaccine Drugs 0.000 description 4
108020004705 Codon Proteins 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 3
108700005091 Immunoglobulin Genes Proteins 0.000 description 3
108091036060 Linker DNA Proteins 0.000 description 3
101150003725 TK gene Proteins 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000003599 detergent Substances 0.000 description 3
230000029087 digestion Effects 0.000 description 3
210000003743 erythrocyte Anatomy 0.000 description 3
239000012362 glacial acetic acid Substances 0.000 description 3
208000016861 hereditary angioedema type 3 Diseases 0.000 description 3
230000028993 immune response Effects 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
230000001524 infective effect Effects 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
230000003902 lesion Effects 0.000 description 3
239000002609 medium Substances 0.000 description 3
239000012071 phase Substances 0.000 description 3
230000003252 repetitive effect Effects 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
239000000523 sample Substances 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
238000001890 transfection Methods 0.000 description 3
210000003934 vacuole Anatomy 0.000 description 3
238000001262 western blot Methods 0.000 description 3
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
208000009889 Herpes Simplex Diseases 0.000 description 2
101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 2
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
101710193484 S-antigen protein Proteins 0.000 description 2
239000012722 SDS sample buffer Substances 0.000 description 2
230000001594 aberrant effect Effects 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
239000012737 fresh medium Substances 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
238000010166 immunofluorescence Methods 0.000 description 2
239000002198 insoluble material Substances 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000004807 localization Effects 0.000 description 2
201000004792 malaria Diseases 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
230000037361 pathway Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
238000000638 solvent extraction Methods 0.000 description 2
241000894007 species Species 0.000 description 2
239000000725 suspension Substances 0.000 description 2
241000712461 unidentified influenza virus Species 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
101150065425 7.5K gene Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
101100328086 Caenorhabditis elegans cla-1 gene Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
101710117490 Circumsporozoite protein Proteins 0.000 description 1
108700010070 Codon Usage Proteins 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 1
101710154606 Hemagglutinin Proteins 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 1
101900111625 Human herpesvirus 1 Envelope glycoprotein D Proteins 0.000 description 1
101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101100268078 Mus musculus Zbtb24 gene Proteins 0.000 description 1
-1 NANP amino acid Chemical class 0.000 description 1
101100335694 Oryza sativa subsp. japonica G1L6 gene Proteins 0.000 description 1
101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
101710176177 Protein A56 Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
102100028029 SCL-interrupting locus protein Human genes 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
108010008038 Synthetic Vaccines Proteins 0.000 description 1
108010078511 TTTAAA -specific type II deoxyribonucleases Proteins 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
108010046722 Thrombospondin 1 Proteins 0.000 description 1
102100036034 Thrombospondin-1 Human genes 0.000 description 1
101900176279 Vaccinia virus Surface antigen S Proteins 0.000 description 1
241000711975 Vesicular stomatitis virus Species 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
238000000137 annealing Methods 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229950004398 broxuridine Drugs 0.000 description 1
244000309466 calf Species 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
101150026451 csp gene Proteins 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000012973 diazabicyclooctane Substances 0.000 description 1
238000007865 diluting Methods 0.000 description 1
230000003028 elevating effect Effects 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000000799 fluorescence microscopy Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000007429 general method Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
239000000185 hemagglutinin Substances 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
238000005286 illumination Methods 0.000 description 1
238000007654 immersion Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
229940042743 immune sera Drugs 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000009545 invasion Effects 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
238000000464 low-speed centrifugation Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000001360 methionine group Chemical class N[C@@H](CCSC)C(=O)* 0.000 description 1
239000000693 micelle Substances 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000000178 monomer Substances 0.000 description 1
238000005192 partition Methods 0.000 description 1
244000052769 pathogen Species 0.000 description 1
239000008188 pellet Substances 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000012545 processing Methods 0.000 description 1
244000000040 protozoan parasite Species 0.000 description 1
238000000746 purification Methods 0.000 description 1
229940124551 recombinant vaccine Drugs 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
210000001563 schizont Anatomy 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
210000003046 sporozoite Anatomy 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
229940125575 vaccine candidate Drugs 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
238000012800 visualization Methods 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Tropical Medicine & Parasitology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AU63701/86A 1985-08-29 1986-08-29 Recombinant vaccinia virus sxpresses hybrid polypeptides on virus infected cell surface Ceased AU594087B2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AUPH2198		1985-08-29
AUPH219885		1985-08-29

Publications (2)

Publication Number	Publication Date
AU6370186A AU6370186A (en)	1987-03-24
AU594087B2 true AU594087B2 (en)	1990-03-01

Family

ID=3771250

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU63701/86A Ceased AU594087B2 (en)	1985-08-29	1986-08-29	Recombinant vaccinia virus sxpresses hybrid polypeptides on virus infected cell surface

Country Status (11)

Country	Link
EP (1)	EP0244427A4 (da)
JP (1)	JPS63500637A (da)
KR (1)	KR880700073A (da)
AU (1)	AU594087B2 (da)
DK (1)	DK219187D0 (da)
ES (1)	ES2002128A6 (da)
FI (1)	FI871885A (da)
IL (1)	IL79880A0 (da)
NZ (1)	NZ217400A (da)
WO (1)	WO1987001386A1 (da)
ZA (1)	ZA866582B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5182211A (en) *	1987-08-07	1993-01-26	Institut Pasteur	Plasmid vectors encoding a protein of a picornavirus
EP0398944A4 (en) *	1988-02-05	1991-09-11	Commonwealth Scientific And Industrial Research Organisation	Gene expression system (particularly for rotavirus vp7 protein) involving a foreign signal peptide and optionally a transmembrane anchor sequence
FR2663228A2 (fr) *	1989-09-29	1991-12-20	Agronomique Inst Nat Rech	Composition immunisante contre la maladie de newcastle et procede de preparation.
EP1523329B1 (en)	2002-07-05	2013-07-24	Folia Biotech Inc.	Adjuvant viral particle
US8101189B2 (en)	2002-07-05	2012-01-24	Folia Biotech Inc.	Vaccines and immunopotentiating compositions and methods for making and using them

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2442271A1 (fr) *	1978-11-27	1980-06-20	Pasteur Institut	Vecteur permettant l'insertion d'un gene procaryote ou eucaryote, et l'excretion de la proteine exprimee
US4603112A (en) *	1981-12-24	1986-07-29	Health Research, Incorporated	Modified vaccinia virus
US4593002A (en) *	1982-01-11	1986-06-03	Salk Institute Biotechnology/Industrial Associates, Inc.	Viruses with recombinant surface proteins
JPH0795954B2 (ja) *	1982-11-30	1995-10-18	アメリカ合衆国	外来性遺伝子発現のためのポックスウイルス組換え体の製造方法
AU569722B2 (en) *	1983-01-28	1988-02-18	Saramane Pty Ltd	Expression of plasmodium falciparum polypeptides from cloned cdna
EP0162738A1 (en) *	1984-04-09	1985-11-27	MOLECULAR GENETICS RESEARCH & DEVELOPMENT LIMITED PARTNERSHIP	Production of pseudorabies virus subunit vaccines
FR2563434B1 (fr) *	1984-04-25	1986-07-25	Transgene Sa	Vaccin contre la rage et procede pour sa preparation

1986
- 1986-08-28 IL IL79880A patent/IL79880A0/xx unknown
- 1986-08-29 AU AU63701/86A patent/AU594087B2/en not_active Ceased
- 1986-08-29 NZ NZ217400A patent/NZ217400A/xx unknown
- 1986-08-29 ZA ZA866582A patent/ZA866582B/xx unknown
- 1986-08-29 ES ES8601549A patent/ES2002128A6/es not_active Expired
- 1986-08-29 WO PCT/AU1986/000256 patent/WO1987001386A1/en not_active Application Discontinuation
- 1986-08-29 JP JP61505157A patent/JPS63500637A/ja active Pending
- 1986-08-29 EP EP19860905164 patent/EP0244427A4/en not_active Withdrawn
1987
- 1987-04-20 KR KR1019870700378A patent/KR880700073A/ko not_active Application Discontinuation
- 1987-04-29 FI FI871885A patent/FI871885A/fi not_active IP Right Cessation
- 1987-04-29 DK DK219187A patent/DK219187D0/da not_active Application Discontinuation

Also Published As

Publication number	Publication date
ZA866582B (en)	1987-04-29
AU6370186A (en)	1987-03-24
FI871885A0 (fi)	1987-04-29
WO1987001386A1 (en)	1987-03-12
EP0244427A1 (en)	1987-11-11
DK219187A (da)	1987-04-29
JPS63500637A (ja)	1988-03-10
NZ217400A (en)	1989-09-27
IL79880A0 (en)	1986-11-30
DK219187D0 (da)	1987-04-29
EP0244427A4 (en)	1989-04-27
FI871885A (fi)	1987-04-29
KR880700073A (ko)	1988-02-15
ES2002128A6 (es)	1988-07-16

Publication	Publication Date	Title
JP3051130B2 (ja)	2000-06-12	組換えコクシジウム症ワクチン類
Langford et al.	1986	Anchoring a secreted plasmodium antigen on the surface of recombinant vaccinia virus-infected cells increases its immunogenicity
CA2025598C (en)	2001-02-27	Chimaeric hepadnavirus core antigen proteins
US6958235B1 (en)	2005-10-25	Recombinant protein containing a C-terminal fragment of plasmodium MSP-1
US5656485A (en)	1997-08-12	Eimeria antigenic composition which elicits antibodies against avian coccidiosis
PH25993A (en)	1992-01-13	Cloning of DNA for protozoal antigens
US6551586B1 (en)	2003-04-22	Malaria vaccine based upon the addition of a MSA1 peptide
AU594087B2 (en)	1990-03-01	Recombinant vaccinia virus sxpresses hybrid polypeptides on virus infected cell surface
AU615451B2 (en)	1991-10-03	Immunogenic recombinant yeast expression product and method for purifying it
US5403581A (en)	1995-04-04	Coccidiosis vaccines
US6933130B1 (en)	2005-08-23	Recombinants process for preparing a complete malaria antigen, gp190/MSP1
Bathurst et al.	1993	An experimental vaccine cocktail for Plasmodium falciparum malaria
WO1988002757A1 (en)	1988-04-21	Hybrid proteins or polypeptides
US5217898A (en)	1993-06-08	Expression of the P. falciparum transmission-blocking antigen in yeast
EP0474891A1 (en)	1992-03-18	Vectors for expression of malarial antigens on the surface of Salmonella vaccine strains
US20040063190A1 (en)	2004-04-01	Preparation and usage of plasmodium fusion antigen
CZ337897A3 (cs)	1998-04-15	Modifikované polypeptidy vykazující zvýšenou imunogenicitu
WO1988005817A1 (en)	1988-08-11	Expression of the p. falciparum circumsporozoite protein by yeast
US5393523A (en)	1995-02-28	Plasmodium falciparum vaccine comprising a recombinant histidine-rich protein-HRP-II
Howard et al.	1986	Conservation and antigenicity of N-terminal sequences of GP185 from different Plasmodium falciparum isolates
Yang et al.	1997	Addition of the MSA1 signal and anchor sequences to the malaria merozoite surface antigen 1 C-terminal region enhances immunogenicity when expressed by recombinant vaccinia virus
AU604711B2 (en)	1991-01-03	Novel vaccines
AU747818B2 (en)	2002-05-23	Vaccines
NO871737L (no)	1987-06-15	Rekombinant virus.
AU8150687A (en)	1988-05-06	Hybrid proteins or polypeptides